Did I miss the buyout memo? I’d worry about us getting bought out at a price making it worthwhile...let alone keeping your job. Not a lot to get excited about these days and the future doesn’t look all that great. Oh I forgot...the 4th to market PD1 will save us.
Haha, interesting the reactions didn't show up in clinicals. I am hearing combination of screening, pre-meds and/or slowing infusion has solved the issues.
Should have had that warning from the launch. We still have an advantage over Emend with our dosage form not requiring IV fluids which is huge right now and less drug interactions, and when Cinvanti launches, they use soybean oil too.